Dimensional Fund Advisors LP lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 0.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 475,562 shares of the medical instruments supplier’s stock after acquiring an additional 3,229 shares during the period. Dimensional Fund Advisors LP’s holdings in Becton Dickinson and were worth $124,117,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fundsmith Equity Fund L.P. bought a new stake in shares of Becton Dickinson and during the 2nd quarter worth about $894,775,000. Hudson Bay Capital Management LP boosted its stake in Becton Dickinson and by 119.9% during the 2nd quarter. Hudson Bay Capital Management LP now owns 166,094 shares of the medical instruments supplier’s stock valued at $39,789,000 after purchasing an additional 90,564 shares during the period. Kiwi Wealth Investments Limited Partnership bought a new stake in Becton Dickinson and during the 2nd quarter valued at approximately $9,161,000. Spinnaker Trust boosted its stake in Becton Dickinson and by 46.3% during the 3rd quarter. Spinnaker Trust now owns 14,922 shares of the medical instruments supplier’s stock valued at $3,894,000 after purchasing an additional 4,725 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in Becton Dickinson and by 9.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 871,363 shares of the medical instruments supplier’s stock valued at $226,999,000 after purchasing an additional 76,560 shares during the period. Institutional investors own 85.19% of the company’s stock.
Shares of BDX stock opened at $241.23 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 0.90. Becton Dickinson and Co has a 12 month low of $209.91 and a 12 month high of $265.87. The company has a market capitalization of $65.70 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 1.69 and a beta of 1.21.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Shareholders of record on Monday, December 10th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.28%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.25%.
In other Becton Dickinson and news, EVP James W. Borzi sold 5,887 shares of the firm’s stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $252.37, for a total value of $1,485,702.19. Following the completion of the sale, the executive vice president now owns 6,013 shares in the company, valued at approximately $1,517,500.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $245.83, for a total value of $511,326.40. Following the completion of the sale, the senior vice president now owns 4,497 shares of the company’s stock, valued at approximately $1,105,497.51. The disclosure for this sale can be found here. Insiders sold a total of 81,795 shares of company stock valued at $19,571,318 in the last quarter. Corporate insiders own 1.00% of the company’s stock.
Several brokerages recently weighed in on BDX. Wells Fargo & Co increased their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Piper Jaffray Companies decreased their target price on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Barclays began coverage on Becton Dickinson and in a research note on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price for the company. KeyCorp increased their target price on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a research note on Thursday, November 8th. Finally, Deutsche Bank began coverage on Becton Dickinson and in a research note on Thursday. They set a “buy” rating for the company. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $254.20.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.